Search research articles
Contact Us
Filters
Showing results (151-160 of 165) with videos related to
Page
of 17
Sort By:
JAMA Network Open
|
August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial
Cynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Science Translational Medicine
|
October 29, 2025
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma
Seblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, et al.
The New England Journal of Medicine
|
December 17, 2020
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
The Journal of Infectious Diseases
|
July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
The Lancet. Infectious Diseases
|
July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
Gary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.
Molecular Cancer Therapeutics
|
May 14, 2025
A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint Therapies
Keith Abayasiriwardana, Lei Wu, Hanane Laklai, et al.
The Lancet. Infectious Diseases
|
September 5, 2024
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial
Flonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, et al.
The New England Journal of Medicine
|
September 29, 2021
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
Science Translational Medicine
|
November 6, 2024
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection
Christopher D Petro, Andrea T Hooper, Avery Peace, et al.
Cell
|
June 23, 2021
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
Richard Copin, Alina Baum, Elzbieta Wloga, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 165) with videos related to
Sort By:
Page
of 17
JAMA Network Open
|
August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial
Cynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Science Translational Medicine
|
October 29, 2025
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma
Seblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, et al.
The New England Journal of Medicine
|
December 17, 2020
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
The Journal of Infectious Diseases
|
July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
The Lancet. Infectious Diseases
|
July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
Gary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.
Molecular Cancer Therapeutics
|
May 14, 2025
A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint Therapies
Keith Abayasiriwardana, Lei Wu, Hanane Laklai, et al.
The Lancet. Infectious Diseases
|
September 5, 2024
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial
Flonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, et al.
The New England Journal of Medicine
|
September 29, 2021
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
Science Translational Medicine
|
November 6, 2024
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection
Christopher D Petro, Andrea T Hooper, Avery Peace, et al.
Cell
|
June 23, 2021
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
Richard Copin, Alina Baum, Elzbieta Wloga, et al.
Page
of 17